Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription 29.10.2018 2 Am J Dermatopathol 1 Arch Pathol Lab Med 1 BMC Cancer 1 Br J Dermatol 2 Eur J Dermatol 3 J Am Acad Dermatol 1 J Cell Physiol 2 J Clin Oncol 1 Lancet Oncol 2 Melanoma Res 3 Nat Med 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Dermatopathol

1. STICCO KL, Feiner A, Chen S
   Melanocytic Nevus Does Not Metastasize!
   Am J Dermatopathol. 2018;40:630.
   PubMed     Text format    
   
   
2. HELM TN, Helm KF
   Spitz Nevus Intermingling With Hemangioma, Angiomatoid Spitz Nevus, Angiotropism, and Vascular Co-option Viewed With Differing Availability Heuristics.
   Am J Dermatopathol. 2018;40:465-467.
   PubMed     Text format    
   
   

   
   Arch Pathol Lab Med

3. LEE JJ, Lian CG
   Molecular Testing for Cutaneous Melanoma: An Update and Review.
   Arch Pathol Lab Med. 2018 Oct 24. doi: 10.5858/arpa.2018-0038.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

4. KHONG B, Lawson BO, Ma J, McGovern C, et al
   Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
   BMC Cancer. 2018;18:1007.
   PubMed     Text format     Abstract available
   
   

   
   Br J Dermatol

5. VERYKIOU S, Alexander M, Edwards N, Plummer R, et al
   Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
   Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17333.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Dermatol

6. SOARES AM, Szejnfeld VL, Enokihara MY, Michalany N, et al
   High serum 25-hydroxyvitamin D concentration in patients with a recent diagnosis of non-melanoma skin cancer: a case-control study.
   Eur J Dermatol. 2018 Oct 23. pii: ejd.2018.3401. doi: 10.1684/ejd.2018.3401.
   PubMed     Text format     Abstract available
   
   
7. DE CASTRO ARAUJO BL, Santos Thuler LC, De Melo AC
   Prognostic impact of tumescent local anaesthesia on survival and recurrence of melanoma following lymphadenectomy.
   Eur J Dermatol. 2018 Oct 23. pii: ejd.2018.3414. doi: 10.1684/ejd.2018.3414.
   PubMed     Text format    
   
   

   
   J Am Acad Dermatol

8. CHERAGHLOU S, Agogo GO, Girardi M
   Treatment of primary non-metastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival.
   J Am Acad Dermatol. 2018 Oct 23. pii: S0190-9622(18)32760.
   PubMed     Text format     Abstract available
   
   
9. VASICEK B, Erickson T, Lake E
   In Response to "Descriptive Survival Study of Nail Melanoma Patients Treated With Functional Surgery vs Distal Amputation".
   J Am Acad Dermatol. 2018 Oct 22. pii: S0190-9622(18)32751.
   PubMed     Text format    
   
   
10. BOOZALIS E, Shah AA, Wigley F, Kang S, et al
    Morphea and systemic sclerosis are associated with an increased risk of melanoma and non-melanoma skin cancer.
    J Am Acad Dermatol. 2018 Oct 20. pii: S0190-9622(18)32755.
    PubMed     Text format    
    
    

    
    J Cell Physiol

11. MOHAMMADPOUR A, Derakhshan M, Darabi H, Hedayat P, et al
    Melanoma: Where we are and where we go.
    J Cell Physiol. 2018 Oct 26. doi: 10.1002/jcp.27286.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

12. DAVAR D, Wang H, Chauvin JM, Pagliano O, et al
    Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
    J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632.
    PubMed     Text format     Abstract available
    
    
13. HAUSCHILD A, Dummer R, Schadendorf D, Santinami M, et al
    Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

14. HODI FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2018 Oct 18. pii: S1470-2045(18)30700.
    PubMed     Text format     Abstract available
    
    

    
    Melanoma Res

15. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
    Melanoma Res. 2018 Oct 22. doi: 10.1097/CMR.0000000000000528.
    PubMed     Text format     Abstract available
    
    
16. MARCOVAL J, Sabate-Llobera A, Bermejo J, Fornons-Servent R, et al
    Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
    Melanoma Res. 2018 Oct 24. doi: 10.1097/CMR.0000000000000530.
    PubMed     Text format     Abstract available
    
    

    
    Nat Med

17. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0252.
    PubMed     Text format     Abstract available
    
    
18. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0251.
    PubMed     Text format     Abstract available
    
    
19. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Oct 17. pii: 10.1038/s41591-018-0247.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

20. WIKSTROM JD, Lundeberg L, Frohm-Nilsson M, Girnita A, et al
    Differences in cutaneous melanoma treatment and patient satisfaction.
    PLoS One. 2018;13:e0205517.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: